PL1801209T3 - Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej - Google Patents

Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej

Info

Publication number
PL1801209T3
PL1801209T3 PL05781421T PL05781421T PL1801209T3 PL 1801209 T3 PL1801209 T3 PL 1801209T3 PL 05781421 T PL05781421 T PL 05781421T PL 05781421 T PL05781421 T PL 05781421T PL 1801209 T3 PL1801209 T3 PL 1801209T3
Authority
PL
Poland
Prior art keywords
coding sequence
protein coding
genomic rna
virus genomic
hepatitis
Prior art date
Application number
PL05781421T
Other languages
English (en)
Inventor
Takaji Wakita
Takanobu Kato
Tomoko Date
Michiko Miyamoto
Ralf Bartenschlager
Jun-Ichi Tanabe
Saburo Sone
Original Assignee
Toray Industries
Tokyo Metropolitan Inst Medical Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Tokyo Metropolitan Inst Medical Science filed Critical Toray Industries
Publication of PL1801209T3 publication Critical patent/PL1801209T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL05781421T 2004-08-24 2005-08-24 Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej PL1801209T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2004243975 2004-08-24
JP2004290801 2004-10-01
JP2005069527 2005-03-11
JP2005069725 2005-03-11
PCT/JP2005/015833 WO2006022422A1 (ja) 2004-08-24 2005-08-24 自律複製能を有する改変されたヒトｃ型肝炎ウイルスゲノムrna
EP05781421A EP1801209B1 (en) 2004-08-24 2005-08-24 Modified human hepatitis c virus genomic rna having autonomous replicative competence

Publications (1)

Publication Number Publication Date
PL1801209T3 true PL1801209T3 (pl) 2011-07-29

Family

ID=35967617

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05781421T PL1801209T3 (pl) 2004-08-24 2005-08-24 Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej

Country Status (12)

Country Link
US (2) US8454973B2 (pl)
EP (1) EP1801209B1 (pl)
JP (1) JP4931591B2 (pl)
KR (1) KR101262773B1 (pl)
CN (1) CN101048502B (pl)
AT (1) ATE499442T1 (pl)
AU (1) AU2005275713B2 (pl)
CA (1) CA2578021C (pl)
DE (1) DE602005026545D1 (pl)
PL (1) PL1801209T3 (pl)
PT (1) PT1801209E (pl)
WO (1) WO2006022422A1 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038129A2 (en) * 2004-10-01 2006-04-13 Novartis Vaccines And Diagnostics Srl Hepatitis c virus replication system
US7674612B2 (en) 2005-03-04 2010-03-09 The Rockefeller University Infectious, chimeric hepatitis C virus, methods of producing the same and methods of use thereof
EP2578702A1 (en) 2006-02-16 2013-04-10 454 Life Sciences Corporation System and method for correcting primer extension errors in nucleic acid sequence data
US8364417B2 (en) 2007-02-15 2013-01-29 454 Life Sciences Corporation System and method to correct out of phase errors in DNA sequencing data by use of a recursive algorithm
JP2008161080A (ja) * 2006-12-27 2008-07-17 Japan Health Science Foundation Ｃ型肝炎ウイルス阻害剤を検出するためのアッセイ方法
US8454974B2 (en) 2007-04-13 2013-06-04 Hvidovre Hospital Adaptive mutations allow establishment of JFH1-based cell culture systems for hepatitis C virus genotype 4A
US8945584B2 (en) 2007-04-13 2015-02-03 Hvidovre Hospital Cell culture system of a hepatitis C genotype 3a and 2a chimera
CN101688197A (zh) * 2007-04-27 2010-03-31 株式会社先端生命科学研究所 Hcv基因
US8618275B2 (en) 2007-05-18 2013-12-31 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 5A
JP5657251B2 (ja) * 2007-07-13 2015-01-21 国立感染症研究所長 エピトープタグ化ｃ型肝炎ウイルス粒子の作製と利用
CN101809033A (zh) * 2007-07-25 2010-08-18 日本国立感染症研究所 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途
US8569472B2 (en) 2007-12-20 2013-10-29 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 6A
EP2235164A1 (en) * 2007-12-20 2010-10-06 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 1a and 1b
JP5593220B2 (ja) * 2008-04-25 2014-09-17 東レ株式会社 Ｃ型肝炎ウイルス由来のキメラ遺伝子を含む核酸
US8663653B2 (en) 2008-08-15 2014-03-04 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 2B
US8506969B2 (en) 2008-08-15 2013-08-13 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 7a
DK2862876T3 (en) 2008-09-30 2016-05-23 Toray Industries Antibody binding to envelope protein 2 of hepatitis C virus and method for identifying the genotype of hepatitis C virus using the same
US8772022B2 (en) 2008-10-03 2014-07-08 Hvidovre Hospital Hepatitis C virus expressing reporter tagged NS5A protein
JP5692738B2 (ja) * 2009-07-28 2015-04-01 国立大学法人 鹿児島大学 ウイルスの濃縮方法および磁性体組成物
EP2484378A4 (en) 2009-09-30 2013-05-22 Toray Industries HEPATITIS C VIRUS VACCINE COMPOSITION
CN102596996B (zh) 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
US20120035062A1 (en) 2010-06-11 2012-02-09 Life Technologies Corporation Alternative nucleotide flows in sequencing-by-synthesis methods
EP2626426A4 (en) * 2010-10-08 2014-04-02 Advanced Life Science Inst Inc HEPATITIS C VIRUS-GEN
EP2633470B1 (en) 2010-10-27 2016-10-26 Life Technologies Corporation Predictive model for use in sequencing-by-synthesis
US10273540B2 (en) 2010-10-27 2019-04-30 Life Technologies Corporation Methods and apparatuses for estimating parameters in a predictive model for use in sequencing-by-synthesis
WO2012118555A1 (en) 2010-12-29 2012-09-07 Life Technologies Corporation Time-warped background signal for sequencing-by-synthesis operations
US20130060482A1 (en) 2010-12-30 2013-03-07 Life Technologies Corporation Methods, systems, and computer readable media for making base calls in nucleic acid sequencing
WO2012092515A2 (en) 2010-12-30 2012-07-05 Life Technologies Corporation Methods, systems, and computer readable media for nucleic acid sequencing
EP2658999B1 (en) 2010-12-30 2019-03-13 Life Technologies Corporation Models for analyzing data from sequencing-by-synthesis operations
WO2012133735A1 (ja) 2011-03-31 2012-10-04 国立感染症研究所長が代表する日本国 遺伝子型１ｂのＣ型肝炎ウイルスゲノム由来の核酸を含む核酸構築物、及び該核酸構築物が導入されたＣ型肝炎ウイルスゲノム複製細胞、並びに感染性Ｃ型肝炎ウイルス粒子の製造方法
WO2012138921A1 (en) 2011-04-08 2012-10-11 Life Technologies Corporation Phase-protecting reagent flow orderings for use in sequencing-by-synthesis
WO2012165542A1 (ja) 2011-05-31 2012-12-06 国立感染症研究所長が代表する日本国 Ｃ型肝炎ウイルスｊ６ｃｆ株ゲノム由来の変異体レプリコン
CA2847115A1 (en) 2011-08-31 2013-03-07 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Nucleic acid construct comprising nucleic acid derived from genome of hepatitis c virus of genotype 3a
US20150087537A1 (en) 2011-08-31 2015-03-26 Life Technologies Corporation Methods, Systems, Computer Readable Media, and Kits for Sample Identification
US10704164B2 (en) 2011-08-31 2020-07-07 Life Technologies Corporation Methods, systems, computer readable media, and kits for sample identification
JP2015509000A (ja) * 2012-01-13 2015-03-26 ギリアド ファーマセット エルエルシー Ｈｃｖポリメラーゼ複合体の結晶構造および使用方法
US9646132B2 (en) 2012-05-11 2017-05-09 Life Technologies Corporation Models for analyzing data from sequencing-by-synthesis operations
US10329608B2 (en) 2012-10-10 2019-06-25 Life Technologies Corporation Methods, systems, and computer readable media for repeat sequencing
US20140296080A1 (en) 2013-03-14 2014-10-02 Life Technologies Corporation Methods, Systems, and Computer Readable Media for Evaluating Variant Likelihood
US9926597B2 (en) 2013-07-26 2018-03-27 Life Technologies Corporation Control nucleic acid sequences for use in sequencing-by-synthesis and methods for designing the same
JP6532456B2 (ja) 2013-10-04 2019-06-19 ライフ テクノロジーズ コーポレーション 終止化学を用いる配列決定における整相効果（ｐｈａｓｉｎｇ ｅｆｆｅｃｔｓ）をモデル化するための方法及びシステム
WO2016060974A1 (en) 2014-10-13 2016-04-21 Life Technologies Corporation Methods, systems, and computer-readable media for accelerated base calling
EP4220645A3 (en) 2015-05-14 2023-11-08 Life Technologies Corporation Barcode sequences, and related systems and methods
US10619205B2 (en) 2016-05-06 2020-04-14 Life Technologies Corporation Combinatorial barcode sequences, and related systems and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4021493B2 (ja) * 1996-11-08 2007-12-12 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、レプリゼンテッド バイ ザ セクレタリー、 デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ Ｃ型肝炎ウイルス様粒子の合成および精製
WO2000075338A2 (en) * 1999-06-04 2000-12-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services CLONED GENONE OF INFECTIOUS HEPATITIS C VIRUS OF GENOTYPE 2a AND USES THEREOF
US7329408B2 (en) 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies
IL137522A (en) 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu Human monoclonal antibody against hepatitis c virus e2 glycoprotein
JP4880116B2 (ja) * 2000-12-01 2012-02-22 財団法人 東京都医学総合研究所 劇症ｃ型肝炎ウイルス株の遺伝子
AU2003230790A1 (en) 2002-04-03 2003-10-20 Smithkline Beecham Corporation Hepatitis c virus sub-genomic replicons
WO2004104198A1 (ja) * 2003-05-26 2004-12-02 Toray Industries, Inc. 遺伝子型2aのC型肝炎ウイルス（HCV）ゲノム由来の核酸を含む核酸構築物、及び該核酸構築物を導入した細胞
WO2006038129A2 (en) * 2004-10-01 2006-04-13 Novartis Vaccines And Diagnostics Srl Hepatitis c virus replication system
US7674612B2 (en) * 2005-03-04 2010-03-09 The Rockefeller University Infectious, chimeric hepatitis C virus, methods of producing the same and methods of use thereof
JP5593220B2 (ja) * 2008-04-25 2014-09-17 東レ株式会社 Ｃ型肝炎ウイルス由来のキメラ遺伝子を含む核酸

Also Published As

Publication number Publication date
US20090176200A1 (en) 2009-07-09
KR101262773B1 (ko) 2013-05-10
CA2578021A1 (en) 2006-03-02
KR20070045333A (ko) 2007-05-02
CA2578021C (en) 2014-11-18
WO2006022422A1 (ja) 2006-03-02
HK1112481A1 (en) 2008-09-05
PT1801209E (pt) 2011-05-26
US8454973B2 (en) 2013-06-04
ATE499442T1 (de) 2011-03-15
AU2005275713A1 (en) 2006-03-02
EP1801209B1 (en) 2011-02-23
AU2005275713B2 (en) 2010-08-05
JP4931591B2 (ja) 2012-05-16
US9175269B2 (en) 2015-11-03
EP1801209A4 (en) 2007-12-05
CN101048502B (zh) 2012-03-21
CN101048502A (zh) 2007-10-03
US20130115592A1 (en) 2013-05-09
DE602005026545D1 (de) 2011-04-07
JPWO2006022422A1 (ja) 2008-05-08
EP1801209A1 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
PT1801209E (pt) Arn gen?mico do v?rus humano modificado da hepatite c com capacidade de replica??o aut?noma
WO2009014216A1 (ja) Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
Epstein et al. Identification of GBV-D, a novel GB-like flavivirus from old world frugivorous bats (Pteropus giganteus) in Bangladesh
Ezelle et al. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
JP2008516610A5 (pl)
WO2004111082A3 (fr) Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
Naderi et al. Hepatitis C virus and vaccine development
ATE555800T1 (de) Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung
US20150152392A1 (en) Hcv full-length infectious cell culture systems and applications thereof
Wakita Cell culture systems of HCV using JFH-1 and other strains
Varshney et al. A review on an update of NS5B polymerase hepatitis C virus inhibitors
Imhof et al. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6
EP1930416A4 (en) NEW RECOMBINANT PARTICLE SIMILAR TO HUMAN HEPATITIS C VIRUS AND METHOD FOR THE MANUFACTURE THEREOF
WO2008136470A1 (ja) Ｈｃｖ遺伝子
WO2005032329A3 (en) Methods and compositions for identifying anti-hcv agents
Lattwein et al. Pestivirus virion morphogenesis in the absence of uncleaved nonstructural protein 2-3
Suzuki et al. Positively selected amino acid sites in the entire coding region of hepatitis C virus subtype 1b
Pham et al. Efficient hepatitis C virus genotype 1b core-NS5A recombinants permit efficacy testing of protease and NS5A inhibitors
Bittar et al. Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response
WO2016066171A1 (en) Optimized hcv full-length infectious cell culture systems and applications thereof
CN104126008A (zh) 包含来自基因型3a的丙型肝炎病毒基因组的核酸的核酸构建物
Sarwar et al. NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b
Alaee et al. Immunoreactivity assessment of hepatitis C virus NS3 protease and NS5A proteins expressed in TOPO cloning system
Cuevas et al. Combined therapy of interferon plus ribavirin promotes multiple adaptive solutions in hepatitis C virus